Literature DB >> 23460744

Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

Indu R Ramachandran1, Anna Martner, Alexandra Pisklakova, Thomas Condamine, Tess Chase, Thomas Vogl, Johannes Roth, Dmitry Gabrilovich, Yulia Nefedova.   

Abstract

Myeloid-derived suppressor cells (MDSC) are one of the major factors limiting the immune response in cancer. However, their role in bone marrow (BM), the site of primary localization of multiple myeloma (MM), is poorly understood. In this study, we found a significant accumulation of CD11b(+)CD14(-)CD33(+) immunosuppressive MDSC in BM of patients with newly diagnosed MM. To assess the possible role of MDSC in MM, we used immunocompetent mouse models. Immunosuppressive MDSC accumulated in BM of mice as early as 1 wk after tumor inoculation. S100A9 knockout (KO) mice, which are deficient in their ability to accumulate MDSC in tumor-bearing hosts, demonstrated reduced MDSC accumulation in BM after injection of MM cells compared with wild-type mice. Growth of the immunogenic MM cells was significantly reduced in S100A9KO mice. This effect was associated with the accumulation of Ag-specific CD8(+) T cells in BM and spleens of S100A9KO mice, but not wild-type mice, and was abrogated by the administration of anti-CD8 Ab or adoptive transfer of MDSC. Thus, the accumulation of MDSC at early stages of MM plays a critical role in MM progression and suggests that MDSC can be considered a possible therapeutic target in this disease.

Entities:  

Mesh:

Year:  2013        PMID: 23460744      PMCID: PMC3608837          DOI: 10.4049/jimmunol.1203373

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.

Authors:  D Mougiakakos; R Jitschin; L von Bahr; I Poschke; R Gary; B Sundberg; A Gerbitz; P Ljungman; K Le Blanc
Journal:  Leukemia       Date:  2012-07-25       Impact factor: 11.528

2.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

3.  Myeloid cell function in MRP-14 (S100A9) null mice.

Authors:  Josie A R Hobbs; Richard May; Kiki Tanousis; Eileen McNeill; Margaret Mathies; Christoffer Gebhardt; Robert Henderson; Matthew J Robinson; Nancy Hogg
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

4.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Authors:  Wan Cheung Cheung; Joong Su Kim; Michael Linden; Liangping Peng; Brian Van Ness; Roberto D Polakiewicz; Siegfried Janz
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Authors:  Sergei Kusmartsev; Yulia Nefedova; Daniel Yoder; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

Review 7.  Immunodeficiency and immunotherapy in multiple myeloma.

Authors:  Guy Pratt; Oliver Goodyear; Paul Moss
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

8.  Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro.

Authors:  Marie-Pierre Manitz; Basil Horst; Stephan Seeliger; Anke Strey; Boris V Skryabin; Matthias Gunzer; Werner Frings; Frank Schönlau; Johannes Roth; Clemens Sorg; Wolfgang Nacken
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

9.  Notch signaling is necessary but not sufficient for differentiation of dendritic cells.

Authors:  Pingyan Cheng; Yulia Nefedova; Lucio Miele; Barbara A Osborne; Dmitry Gabrilovich
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

10.  Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Keren Osman; Matthew D Geller
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

View more
  91 in total

Review 1.  Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.

Authors:  Michaela R Reagan; Lucy Liaw; Clifford J Rosen; Irene M Ghobrial
Journal:  Bone       Date:  2015-02-26       Impact factor: 4.398

Review 2.  Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.

Authors:  N Lendvai; A D Cohen; H J Cho
Journal:  Bone Marrow Transplant       Date:  2015-03-09       Impact factor: 5.483

Review 3.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Authors:  K H Shain; W S Dalton; J Tao
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

Review 4.  Immunopathogenesis and immunotherapy of multiple myeloma.

Authors:  Hideto Tamura
Journal:  Int J Hematol       Date:  2018-01-24       Impact factor: 2.490

Review 5.  Future agents and treatment directions in multiple myeloma.

Authors:  Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

Review 6.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

7.  Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.

Authors:  Maria Ozerova; Yulia Nefedova
Journal:  Leuk Lymphoma       Date:  2019-01-02

8.  Myeloid-derived suppressor cells in the development of lung cancer.

Authors:  Myrna L Ortiz; Lily Lu; Indu Ramachandran; Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2013-10-18       Impact factor: 11.151

9.  E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.

Authors:  Enguang Bi; Rong Li; Laura C Bover; Haiyan Li; Pan Su; Xingzhe Ma; Chunjian Huang; Qiang Wang; Lintao Liu; Maojie Yang; Zhijuan Lin; Jianfei Qian; Weijun Fu; Yong-Jun Liu; Qing Yi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

10.  Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.

Authors:  Xiaolin Hu; Kankana Bardhan; Amy V Paschall; Dafeng Yang; Jennifer L Waller; Mary Anne Park; Asha Nayak-Kapoor; Thomas A Samuel; Scott I Abrams; Kebin Liu
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.